剂量密集替莫唑胺联合拉帕替尼治疗复发室管膜瘤的II期研究
本研究为复发室管膜瘤成人患者的前瞻性II期临床试验,采用剂量密集替莫唑胺联合每日拉帕替尼方案,主要终点为中位无进展生存期。50例患者入组,中位无进展生存期7.8个月(95%CI:5.5,12.2),6个月和12个月无进展生存率分别为55%和38%,出现2例完全缓解和6例部分缓解。结论认为该方案可作为复发室管膜瘤成人患者的挽救治疗方案。
要点
- 中位无进展生存期为7.8个月,6个月和12个月无进展生存率分别为55%和38%。
- 出现2例完全缓解和6例部分缓解,多数患者中重度疼痛及其他疾病相关症状减轻。
- 该联合方案耐受性良好,可作为复发室管膜瘤成人患者的挽救治疗选择。
核心结论
- 剂量密集替莫唑胺联合拉帕替尼在复发室管膜瘤成人患者中显示出临床活性,客观缓解与延长的疾病控制伴随疾病相关症状改善,可作为挽救治疗方案。
研究设计与样本
- 协作性室管膜瘤研究网络开展的前瞻性II期临床试验,入组50例18岁及以上、组织学证实的进展性室管膜瘤或间变性室管膜瘤患者,接受剂量密集替莫唑胺联合每日拉帕替尼治疗,主要终点为中位无进展生存期。
主要发现
- 一半患者为脊髓肿瘤,15例为幕上肿瘤,8例为幕下肿瘤,2例为播散性疾病。
- 中位无进展生存期为7.8个月(95%CI:5.5,12.2),6个月和12个月无进展生存率分别为55%和38%,出现2例完全缓解和6例部分缓解。
- 症状负荷评估显示多数患者中重度疼痛及其他疾病相关症状减轻。
临床怎么用
- 对复发室管膜瘤成人患者,可考虑剂量密集替莫唑胺联合拉帕替尼作为挽救治疗方案。
局限性
- 原文未在摘要中明确报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No standard medical treatment exists for adult patients with recurrent ependymoma, and prospective clinical trials in this population have not succeeded because of its rarity and challenges in accruing patients. The Collaborative Ependymoma Research Network conducted a prospective phase II clinical trial of dose-dense temozolomide (TMZ) and lapatinib, targeting the unmethylated O6-methylguanine-DNA methyltransferase (MGMT) promoter status and increased expression of ErbB2 (human epidermal growth factor receptor 2) and ErbB1 (epidermal growth factor receptor) in ependymomas. METHODS: Patients age 18 or older with histologically proven and progressive ependymoma or anaplastic ependymoma were eligible and received dose-dense TMZ and daily lapatinib. The primary outcome measure was median progression-free survival (PFS). Landmark 6- and 12-month PFS and objective response were measured. Serial assessments of symptom burden using the MD Anderson Symptom Inventory Brain Tumor (MDASI-BT)/MDASI-Spine Tumor modules were collected. RESULTS: The 50 patients enrolled had a median age of 43.5 years, median Karnofsky performance status of 90, and a median of 2 prior relapses. Twenty patients had grade III, 16 grade II, and 8 grade I ependymoma. Half had spinal cord tumors; 15 had a supratentorial tumor, 8 infratentorial, and 2 had disseminated disease. Treatment was well tolerated. The median PFS was 7.8 months (95% CI: 5.5,12.2); the 6- and 12-month PFS rates were 55% and 38%, with 2 complete and 6 partial responses. Measures of symptom burden showed reduction in moderate-severe pain and other disease-related symptoms in most patients. CONCLUSIONS: This treatment, with demonstrated clinical activity with objective responses and prolonged disease control associated with disease-related symptom improvements, is an option as a salvage regimen for adult patients with recurrent ependymoma.
引用
- Gilbert MR, Yuan Y, Wu J, et al. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro Oncol. 2021. PMID: 33085768. doi:10.1093/neuonc/noaa240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。